{"id":"flumist-b-yamagata","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nasal congestion"},{"rate":"20-30","effect":"Runny nose"},{"rate":"10-15","effect":"Sore throat"},{"rate":"5-10","effect":"Cough"},{"rate":"1-3","effect":"Fever"},{"rate":"1-2","effect":"Wheezing"}]},"_chembl":{"chemblId":"CHEMBL1160385","moleculeType":"Small molecule","molecularWeight":"182.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FluMist contains live, temperature-sensitive attenuated influenza virus strains that replicate in the cooler upper respiratory tract but cannot replicate in the warmer lower respiratory tract, triggering both mucosal and systemic immune responses. The vaccine strain for Yamagata lineage provides protection against influenza B virus of the Yamagata genetic lineage. This intranasal delivery approach induces local IgA antibodies and cellular immunity in addition to systemic responses.","oneSentence":"FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened influenza virus strains intranasally.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:53.203Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza B disease caused by Yamagata lineage virus in eligible populations"}]},"trialDetails":[{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT06863142","phase":"PHASE1","title":"Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-28","conditions":"Influenza Prevention, Seasonal Influenza","enrollment":45},{"nctId":"NCT05968989","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-08-09","conditions":"Influenza","enrollment":30},{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT03927131","phase":"PHASE3","title":"Safety and Immunogenicity of the Butantan Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2021-05-12","conditions":"Influenza, Human","enrollment":5822},{"nctId":"NCT03849560","phase":"PHASE2, PHASE3","title":"Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2016-11","conditions":"Influenza","enrollment":612},{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":"Influenza","enrollment":839},{"nctId":"NCT05895955","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":"Influenza","enrollment":290},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT05501561","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-08-25","conditions":"Influenza, Human","enrollment":1056},{"nctId":"NCT03744104","phase":"PHASE3","title":"A Clinical Trial of A Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-10-11","conditions":"Influenza","enrollment":2688},{"nctId":"NCT04363359","phase":"PHASE2","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2020-01-15","conditions":"Influenza","enrollment":1980},{"nctId":"NCT02677493","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-10","conditions":"Influenza","enrollment":1794},{"nctId":"NCT05138705","phase":"PHASE4","title":"Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2021-12-14","conditions":"Influenza, Human","enrollment":380},{"nctId":"NCT03438487","phase":"","title":"Flucelvax (TIVc or QIVc) Pregnancy Registry","status":"COMPLETED","sponsor":"Seqirus","startDate":"2017-09-01","conditions":"Influenza, Human, Pregnancy, Birth Defect","enrollment":692},{"nctId":"NCT05212623","phase":"PHASE1","title":"A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-10-26","conditions":"Influenza","enrollment":120},{"nctId":"NCT03445468","phase":"PHASE3","title":"Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2017-09-20","conditions":"Influenza, Human","enrollment":379},{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":"Influenza","enrollment":1503},{"nctId":"NCT03859141","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-02-06","conditions":"Seasonal Influenza","enrollment":2340},{"nctId":"NCT03853993","phase":"PHASE3","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-01-23","conditions":"Seasonal Influenza","enrollment":2380},{"nctId":"NCT03143101","phase":"PHASE4","title":"Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2017-05-08","conditions":"Influenza, Healthy","enrollment":200},{"nctId":"NCT01196975","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-01","conditions":"Influenza","enrollment":1707},{"nctId":"NCT01198756","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-01","conditions":"Influenza","enrollment":3109},{"nctId":"NCT01811823","phase":"PHASE4","title":"Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2014-03-31","conditions":"Influenza, HIV, Tuberculosis","enrollment":301},{"nctId":"NCT03016143","phase":"PHASE2","title":"Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2016-10","conditions":"Influenza","enrollment":300},{"nctId":"NCT00952705","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-08","conditions":"Healthy or Stable Underlying Chronic Medical Condition","enrollment":1800},{"nctId":"NCT03028116","phase":"PHASE1","title":"Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"Research Institute for Biological Safety Problems","startDate":"2016-05","conditions":"Influenza, Human","enrollment":44},{"nctId":"NCT01712984","phase":"PHASE3","title":"Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-10","conditions":"Influenza","enrollment":3360},{"nctId":"NCT00860067","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-03","conditions":"Healthy or Stable Underlying Chronic Medical Condition","enrollment":1800},{"nctId":"NCT01091246","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2010-03","conditions":"Healthy or Stable Chronic Illness","enrollment":2312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FluMist"],"phase":"phase_3","status":"active","brandName":"FluMist/B/Yamagata","genericName":"FluMist/B/Yamagata","companyName":"MedImmune LLC","companyId":"medimmune-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"FluMist is a live attenuated influenza vaccine that stimulates immune response by delivering weakened influenza virus strains intranasally. Used for Prevention of influenza B disease caused by Yamagata lineage virus in eligible populations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}